Cargando…
Sildenafil: From angina to SARS-CoV-2
Sildenafil was first examined as an alternative to nitrates for the management of angina pectoris and hypertension and eventually developed into an oral therapeutic agent used for the treatment of erectile dysfunction. There are appropriate indicators that PDE5 inhibitors may also modify the detrime...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sexologies. Published by Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162896/ http://dx.doi.org/10.1016/j.sexol.2021.05.002 |
_version_ | 1783700801203470336 |
---|---|
author | Khairy, G.M. El-Sheikh, S.M.A. Eleiwa, N.Z. Galal, A.A.A. |
author_facet | Khairy, G.M. El-Sheikh, S.M.A. Eleiwa, N.Z. Galal, A.A.A. |
author_sort | Khairy, G.M. |
collection | PubMed |
description | Sildenafil was first examined as an alternative to nitrates for the management of angina pectoris and hypertension and eventually developed into an oral therapeutic agent used for the treatment of erectile dysfunction. There are appropriate indicators that PDE5 inhibitors may also modify the detrimental consequences of the immune system over-stimulation, supplying a new chance for their use in SARS-CoV2 patients. The use of sildenafil for the management of SARS-CoV2 has been suggested based on its several mechanisms of action and therapeutic effects and on the clinical features of SARS-CoV2 which similar to those of other pathologies treated with the PDE5 inhibitors. Here we review fundamental highlights in the enhancement of sildenafil for numerous scientific disorders and consider practicable new uses for this versatile drug. |
format | Online Article Text |
id | pubmed-8162896 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Sexologies. Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81628962021-06-01 Sildenafil: From angina to SARS-CoV-2 Khairy, G.M. El-Sheikh, S.M.A. Eleiwa, N.Z. Galal, A.A.A. Sexologies General Review Sildenafil was first examined as an alternative to nitrates for the management of angina pectoris and hypertension and eventually developed into an oral therapeutic agent used for the treatment of erectile dysfunction. There are appropriate indicators that PDE5 inhibitors may also modify the detrimental consequences of the immune system over-stimulation, supplying a new chance for their use in SARS-CoV2 patients. The use of sildenafil for the management of SARS-CoV2 has been suggested based on its several mechanisms of action and therapeutic effects and on the clinical features of SARS-CoV2 which similar to those of other pathologies treated with the PDE5 inhibitors. Here we review fundamental highlights in the enhancement of sildenafil for numerous scientific disorders and consider practicable new uses for this versatile drug. Sexologies. Published by Elsevier Masson SAS. 2021-12 2021-05-28 /pmc/articles/PMC8162896/ http://dx.doi.org/10.1016/j.sexol.2021.05.002 Text en © 2021 Sexologies. Published by Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | General Review Khairy, G.M. El-Sheikh, S.M.A. Eleiwa, N.Z. Galal, A.A.A. Sildenafil: From angina to SARS-CoV-2 |
title | Sildenafil: From angina to SARS-CoV-2 |
title_full | Sildenafil: From angina to SARS-CoV-2 |
title_fullStr | Sildenafil: From angina to SARS-CoV-2 |
title_full_unstemmed | Sildenafil: From angina to SARS-CoV-2 |
title_short | Sildenafil: From angina to SARS-CoV-2 |
title_sort | sildenafil: from angina to sars-cov-2 |
topic | General Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162896/ http://dx.doi.org/10.1016/j.sexol.2021.05.002 |
work_keys_str_mv | AT khairygm sildenafilfromanginatosarscov2 AT elsheikhsma sildenafilfromanginatosarscov2 AT eleiwanz sildenafilfromanginatosarscov2 AT galalaaa sildenafilfromanginatosarscov2 |